Mesoblast | MSB - Ebitda


Mesoblast reported $-17.08M in EBITDA for its fiscal semester ending in June of 2026.





Ebitda Change Date
Avita Medical AUD -9.69M 12.21M Dec/2025
Clinuvel Pharmaceuticals AUD 27.55M 12.65M Jun/2025
Cochlear AUD 306.4M 13.5M Dec/2025
CSL USD 3.13B 1.17B Dec/2025
Pacific Edge NZD -13.97M 332K Sep/2024
Paradigm Biopharmaceuticals AUD -5.86M 3.79M Dec/2024
PYC Therapeutics AUD -22.79M 1.5M Dec/2025
Ramsay Health Care AUD 1.12B 10.6M Dec/2025
Sonic Healthcare AUD 839.07M 51.09M Dec/2024
Starpharma Holdings AUD -4.85M 1.73M Dec/2024
Telix Pharmaceuticals AUD 76.49M 58.07M Jun/2026